Skip to main content

Table 2 Summary of clinical trials targeting TAM receptor activity

From: Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment

TAM Targeting Drug (Drug Type) Target(s) Condition(s) ClincialTrials.gov Identifier(s)
AVB-S6–500 (Axl-Fc fusion protein) Gas6 Ovarian Cancer
Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer
NCT03401528
NCT03607955
NCT03639246
ASLAN-002/BMS-777607 (Small molecule) Met, RON, FLT3, Axl Advanced or Metastatic Solid Tumors NCT00605618
NCT01721148 [162]
BA3011/CAB-AXL-ADC (Antibody-drug conjugate) Axl Solid Tumor
Non-Small Cell Lung Cancer
Castration-Resistant Prostate Cancer
Pancreatic Cancer
NCT03425279
Bemcentinib/BGB324/R428 (Small molecule) Axl Advanced or Metastatic Solid Tumors NCT02424617
NCT02488408
NCT02872259
NCT02922777
NCT03184558
NCT03184571
NCT03649321
NCT03654833
BPI-9016 M (Small molecule) Axl, Met Solid Tumors
Non-Small Cell Lung Cancer
NCT02478866
NCT02929290
CCT301 (CAR-T) Axl Renal Cell Carcinoma NCT03393936
INCB081776 (Small molecule) Axl, MerTK Advanced Solid Tumors NCT03522142
MRX-2843 (Small molecule) MerTK, FLT3 Advanced or Metastatic Solid Tumors NCT03510104
ONO-7475 (Small molecule) Axl, MerTK Advanced or Metastatic Solid Tumors
Acute Leukemia
NCT03176277
NCT03510104
TP-0903 (Small molecule) Axl Advanced Solid Tumors
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
EGFR Positive Non-small Cell Lung Cancer
Colorectal Carcinoma
Recurrent Ovarian Carcinoma
BRAF-Mutated Melanoma
NCT02729298
NCT03572634
  1. TAM receptor-specific targets are bolded. Where available, published results are cited